Product Name:3,5-Difluorophenylboronic acid

IUPAC Name:(3,5-difluorophenyl)boronic acid

CAS:156545-07-2
Molecular Formula:C6H5BF2O2
Purity:95%+
Catalog Number:CM135591
Molecular Weight:157.91

Packing Unit Available Stock Price($) Quantity
CM135591-100g in stock ƀȁ
CM135591-500g in stock ƦɅNJ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:156545-07-2
Molecular Formula:C6H5BF2O2
Melting Point:-
Smiles Code:C1=C(C=C(F)C=C1F)B(O)O
Density:
Catalog Number:CM135591
Molecular Weight:157.91
Boiling Point:
MDL No:MFCD01318138
Storage:

Category Infos

Boronic Acids and Esters
Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
Boronic Acid For Sale
Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.
Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

TAK-861
Takeda announced positive topline results from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1 and intends to rapidly initiate the first global Phase 3 trials of TAK-861 in first half of fiscal year 2024.
Paltusotine
Crinetics’ once-daily oral paltusotine achieved the primary and all secondary endpoints in the phase 3 PATHFNDR-2 study in acromegaly patients.
Acromegaly is a serious rare disease generally caused by a pituitary adenoma, a benign tumor in the pituitary that secretes growth hormone (GH). Excess GH secretion causes excess secretion of IGF-1 from the liver. Prolonged exposure to increased levels of IGF-1 and GH leads to progressive and serious systemic complications, often resulting in bone, joint, cardiovascular, metabolic, cerebrovascular, or respiratory disease. 
Paltusotine is the first oral, once-daily selectively-targeted somatostatin receptor type 2 (SST2) agonist and is currently in investigational Phase 3 studies for acromegaly and a Phase 2 study for carcinoid syndrome.